Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

  • In development
  • GID-TA11424
  • Expected publication date: TBC

Documents

Documents created during the development process.

Declaration of interests

Draft guidance

Declaration of interests

Committee meetings

  • Committee meeting

  • Committee meeting

Notes

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6442